Patients suffering from dental infections and concurrently using immunosuppressive medication are at increased risk of developing systemic streptococcal infections. Tocilizumab is a novel therapeutic agent targeting interleukin-6. We describe a case of streptococcal lung abscesses from a dental focus after use of tocilizumab for treatment of Takayasu Arteritis.

Dental infection control, Lung abscess, Monoclonal antibody
Clinical and Experimental Rheumatology
Department of Virology

de Kruif, M.D, van Gorp, E.C.M, Bel, E.H, Gerlag, D.M, & Kunst, P.W. (2012). Streptococcal lung abscesses from a dental focus following tocilizumab: A case report. Clinical and Experimental Rheumatology, 30(6), 951–953. Retrieved from